Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that it has completed development of its second Unyvero application. The new Unyvero i60 ITI cartridge rapidly identifies more than 90 pathogens and more than 20 resistance markers common in implant and tissue infections. After successfully manufacturing several lots and completing initial verification testing of the cartridge, the Company has initiated a pivotal study using approximately 500 cartridges to validate analytical, technical and clinical performance for CE marking.